Kuros Biosciences AG/Fr. KURN
1D1W1MYTD1Y5YMAX
About Kuros Biosciences AG
Kuros Biosciences AG is a biotechnology company focused on the development and commercialization of novel products for tissue repair and regeneration. The company's portfolio includes biomaterials and biologics aimed at enhancing bone healing in spinal, trauma, and cranio-maxillofacial surgeries. Headquartered in Schlieren, Switzerland, Kuros leverages its proprietary technologies to address unmet clinical needs in bone regeneration. The company's strategic positioning is strengthened by its focus on advanced biomaterial-based solutions, which differentiate its offering in the competitive regenerative medicine market.
- Ticker
- Fr. KURN
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 178
- Headquarters
- Schlieren, Switzerland
- Website
- kurosbio.com
KURN Metrics
BasicAdvanced
CHF 891M
129.97
CHF 0.17
0.76
-
Price and volume
Market cap
CHF 891M
Beta
0.76
52-week high
CHF 34.20
52-week low
CHF 17.69
Average daily volume
178K
Financial strength
Profitability
EBITDA (TTM)
10.703
Gross margin (TTM)
86.37%
Net profit margin (TTM)
5.13%
Operating margin (TTM)
6.07%
Effective tax rate (TTM)
17.23%
Revenue per employee (TTM)
CHF 783,840
Management effectiveness
Valuation
Price to earnings (TTM)
129.97
Price to revenue (TTM)
6.202
Growth
Revenue change (TTM)
42.45%
Earnings per share change (TTM)
-238.27%
3-year revenue growth (CAGR)
90.56%
10-year revenue growth (CAGR)
61.53%
3-year earnings per share growth (CAGR)
-27.09%
10-year earnings per share growth (CAGR)
-27.73%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.